Refractory Partial Seizures
Conditions
Keywords
Partial onset seizures, E2007, perampanel, refractory partial seizures, adjunctive therapy, seizure frequency, reduction in seizure frequency, safety, concomitant AED(s)
Brief summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.
Interventions
DRUGperampanel
2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
DRUGPlacebo
Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
Sponsors
Eisai Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
12 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
1. Provide written informed consent signed by the subject or legal guardian prior to entering the study or undergoing any study procedures (If the written informed consent is provided by the legal guardian because the subject is unable to do so, a written or verbal assent from the subject must also be obtained.). 2. Be considered reliable and willing to be available for the study period and able to record seizures and report AEs them self or have a caregiver who can record seizures and report AEs for them; 3. Male or female and greater than or equal to 12 years of age (within the course of the study), or greater than or equal to 18 years of age (depending on location) at the time of signing the informed consent. 4. Females should be either of non-childbearing potential (defined as having undergone surgical sterilization, or postmenopausal \[age 50 and amenorrheic for 12 months\]) or of childbearing potential. Females of childbearing potential must have a negative serum beta-human chorionic gonadotropin (ß-hCG) at Visit 1 and a negative urine pregnancy test prior to randomization at Visit 2. Female subjects of childbearing potential must agree to be abstinent or to use at least 1 medically acceptable methods of contraception (eg, a double-barrier method \[eg, condom + spermicide, condom + diaphragm with spermicide\], IUD, or have a vasectomised partner) starting at Visit 1 and throughout the entire study period and for 2 months after the last dose of study drug. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously) starting at Visit 1 and continuing throughout the entire study period and for 2 months after the last dose of study drug. (It is not required for male subjects to use contraceptive measures based on preclinical toxicology data.); 5. Have a diagnosis of epilepsy with partial seizures with or without secondarily generalized seizures according to the International League Against Epilepsy's Classification of Epileptic Seizures (1981). Diagnosis should have been established by clinical history and an electroencephalogram (EEG) that is consistent with localization-related epilepsy; normal interictal EEGs will be allowed provided that the subject meets the other diagnosis criterion (ie, clinical history); 6. Have had a computed tomography (CT) or magnetic resonance imaging (MRI) within the last 10 years that ruled out a progressive cause of epilepsy; 7. Have uncontrolled partial seizures despite having been treated with at least 2 different anti-epileptic drugs (AEDs) within approximately the last 2 years; 8. During the 6-week Pre-randomization Phase subjects must have had \>/= 5 partial seizures per 6-week (with \>/=2 partial seizures per each of 3-week period) and with no 25-day seizure-free period in the 6-week period, as documented via a valid seizure diary. Only simple partial seizures with motor signs, complex partial seizures, and complex partial seizures with secondary generalization are counted toward this inclusion; 9. Are currently being treated with stable doses of 1, 2 or a maximum of 3 approved AEDs. Only 1 inducer AED (defined as; carbamazepine, phenytoin, phenobarbital, or primidone only) out of the maximum of 3 AEDs is allowed; 10. Are on a stable dose of the same concomitant AED(s) for 1 month (or no less than 21 days) prior to Visit 1; in the case where a new AED regime has been initiated for a subject, the dose must be stable for 2 months (or no less than 49 days) prior to Visit 1; 11. If on a stable dose (other than intermittent rescue use) of benzodiazepines for epilepsy (or for anxiety or sleep disorders) the prescribed dose must be stable for 1 month (or no less than 21 days) prior to Visit 1. (Note: the use of intermittent rescue benzodiazepines is defined in the exclusion criterion #22 below.) When used in these cases (epilepsy, anxiety or sleep disorders), benzodiazepines will be counted as 1 AED; therefore, only 1 or a maximum of 2 additional approved AEDs will be allowed; 12. A vagal nerve stimulator (VNS) is allowed but it must have been implanted \>/= 5 months prior to Visit 1. Stimulator parameters can not be changed for 1 month (or no less than 21 days) prior to Visit 1 or thereafter during the study.
Exclusion criteria
1. Participated in a study involving administration of an investigational compound or device within 1 month (or no less than 21 days) prior to Visit 1, or within approximately 5 half-lives of the previous investigational compound, whichever is longer; 2. Pregnant and/or lactating; 3. Participated in previous perampanel studies; 4. Presence of nonmotor simple partial seizures only; 5. Presence of primary generalized epilepsies or seizures, such as absences and or myoclonic epilepsies; 6. Presence or previous history of Lennox-Gastaut syndrome; 7. A history of status epilepticus within approximately 12 months prior to Visit 1; 8. Seizure clusters where individual seizures cannot be counted; 9. A history of psychogenic seizures; 10. Evidence of clinically significant disease (eg, cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the Investigator(s) could affect the subject's safety or the study conduct; 11. Scheduled and/or confirmed to have epilepsy surgery within 6 months after Visit 1; however those who have previously documented failed epilepsy surgery will be allowed; 12. Evidence of significant active hepatic disease. Stable elevations of liver enzymes, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) due to concomitant medication(s) will be allowed if they are less than 3 times the upper limit of normal (ULN); 13. Evidence of significant active hematological disease; white blood cell (WBC) count \<= 2500/µL (2.50 1E+09/L) or an absolute neutrophil count \<= 1000/µL (1.00 1E+09/L); 14. A clinically significant ECG abnormality, including prolonged QTc defined as \>450 msec; 15. Suffering from psychotic disorder(s) and/or unstable recurrent affective disorder(s) evident by use of antipsychotics or have had a suicide attempt(s) within the last 2 years. 16. Presence of a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors; 17. History of drug or alcohol dependency or abuse within approximately the last 2 years; 18. Have had multiple drug allergies or a severe drug reaction to an AED(s), including dermatological (eg, Stevens-Johnson syndrome), hematological, or organ toxicity reactions; 19. If felbamate is used as a concomitant AED, subjects must be on felbamate for at least 2 years, with a stable dose for 2 months (or no less than 49 days) prior to Visit 1. They must not have a history of white blood cell (WBC) count below 2500/µL (2.50 1E+09/L), platelets below 100,000, liver function tests (LFTs) above 3 times the upper limit of normal (ULN), or other indication of hepatic or bone marrow dysfunction while receiving felbamate. If patients received felbamate in the past, it must have been discontinued 2 months (or no less than 49 days) prior to Visit 1; 20. Concomitant use of vigabatrin. Subjects who took vigabatrin in the past must be off vigabatrin for approximately 5 months prior to Visit 1 and must have documentation showing no evidence of a vigabatrin associated clinically significant abnormality in a visual perimetry test; 21. Concomitant use of barbiturates (except for seizure control indication) within 1 month (or no less than 21 days) prior to Visit 1; 22. Use of intermittent rescue benzodiazepines (ie, 1-2 doses over a 24-hr period considered one-time rescue) 2 or more times in a 1-month period prior to Visit 1; or 23. Any condition(s) that will make the subject, in the opinion of the Investigator, unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Baseline (Pre-randomization) through Week 19 | Seizure frequency per 28 days was derived from the information recorded in the subject diaries. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Responder Rate | Baseline (Pre-randomization) through Week 19 | The responder rate for the Full ITT Analysis Set from the maintenance LOCF (Last Observation Carried Forward). A responder was a subject who had a 50 percent or greater reduction in seizure frequency per 28 days from the Pre-randomization phase. |
| Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Baseline (Pre-randomization) through Week 19 | Percent Change in the Seizure frequency per 28 days was derived from the information recorded in the subject diaries. |
Countries
Australia, Bulgaria, Czechia, Estonia, Germany, Hong Kong, Hungary, India, Italy, Latvia, Lithuania, Malaysia, Philippines, Poland, Portugal, Romania, Russia, Serbia, South Korea, Spain, Taiwan, Thailand, Ukraine
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Placebo over 19-weeks (during 6-week Titration phase and 13-week Maintenance phase) | 185 |
| Perampanel 2mg Perampanel 2mg daily over 19-weeks (during 6-week Titration phase and 13-week Maintenance phase) | 180 |
| Perampanel 4mg Perampanel 4mg maximum daily dose (Titration from 2mg to 4mg daily over 6-weeks; Maintenance at 4 mg daily over 13-weeks) | 172 |
| Perampanel 8 mg Perampanel 8mg maximum daily dose (Titration from 2mg to 8mg daily over 6-weeks; Maintenance at 8 mg daily over 13-weeks) | 169 |
| Total | 706 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Administrative/Other | 1 | 3 | 1 | 3 |
| Overall Study | Adverse Event | 6 | 10 | 5 | 11 |
| Overall Study | Lack of Efficacy | 0 | 3 | 0 | 1 |
| Overall Study | Lost to Follow-up | 4 | 1 | 0 | 1 |
| Overall Study | Randomized, Not Treated | 2 | 0 | 2 | 2 |
| Overall Study | Withdrawal by Subject | 8 | 9 | 8 | 8 |
Baseline characteristics
| Characteristic | Placebo | Perampanel 2mg | Perampanel 4mg | Perampanel 8 mg | Total |
|---|---|---|---|---|---|
| Age, Customized 18-64 Years | 169 Participants | 156 Participants | 158 Participants | 153 Participants | 636 Participants |
| Age, Customized <18 Years | 14 Participants | 21 Participants | 13 Participants | 12 Participants | 60 Participants |
| Age, Customized >64 Years | 2 Participants | 3 Participants | 1 Participants | 4 Participants | 10 Participants |
| Race/Ethnicity, Customized Asian | 34 Participants | 35 Participants | 37 Participants | 28 Participants | 134 Participants |
| Race/Ethnicity, Customized Chinese | 31 Participants | 25 Participants | 29 Participants | 25 Participants | 110 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 119 Participants | 119 Participants | 105 Participants | 116 Participants | 459 Participants |
| Sex: Female, Male Female | 90 Participants | 95 Participants | 84 Participants | 92 Participants | 361 Participants |
| Sex: Female, Male Male | 95 Participants | 85 Participants | 88 Participants | 77 Participants | 345 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 48 / 185 | 61 / 180 | 66 / 172 | 79 / 169 |
| serious Total, serious adverse events | 9 / 185 | 6 / 180 | 6 / 172 | 6 / 169 |
Outcome results
Primary
Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases)
Seizure frequency per 28 days was derived from the information recorded in the subject diaries.
Time frame: Baseline (Pre-randomization) through Week 19
Population: Full Intent-to-Treat (ITT) Analysis Set - group of subjects who were randomized to study drug, received study drug, and had any seizure frequency data during the Double-blind Phase.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | -10.69 Percent Change |
| Perampanel 2mg | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | -13.63 Percent Change |
| Perampanel 4mg | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | -23.33 Percent Change |
| Perampanel 8 mg | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | -30.80 Percent Change |
Secondary
Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases)
Percent Change in the Seizure frequency per 28 days was derived from the information recorded in the subject diaries.
Time frame: Baseline (Pre-randomization) through Week 19
Population: Full ITT Analysis Set
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | -17.63 Percent Change |
| Perampanel 2mg | Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | -20.50 Percent Change |
| Perampanel 4mg | Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | -31.18 Percent Change |
| Perampanel 8 mg | Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | -38.69 Percent Change |
Secondary
Responder Rate
The responder rate for the Full ITT Analysis Set from the maintenance LOCF (Last Observation Carried Forward). A responder was a subject who had a 50 percent or greater reduction in seizure frequency per 28 days from the Pre-randomization phase.
Time frame: Baseline (Pre-randomization) through Week 19
Population: Full ITT Analysis Set.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Responder Rate | Responders (Yes) | 17.9 Percentage of Participants |
| Placebo | Responder Rate | Non-Responders (No) | 82.1 Percentage of Participants |
| Perampanel 2mg | Responder Rate | Non-Responders (No) | 79.4 Percentage of Participants |
| Perampanel 2mg | Responder Rate | Responders (Yes) | 20.6 Percentage of Participants |
| Perampanel 4mg | Responder Rate | Responders (Yes) | 28.5 Percentage of Participants |
| Perampanel 4mg | Responder Rate | Non-Responders (No) | 71.5 Percentage of Participants |
| Perampanel 8 mg | Responder Rate | Responders (Yes) | 34.9 Percentage of Participants |
| Perampanel 8 mg | Responder Rate | Non-Responders (No) | 65.1 Percentage of Participants |